Evidence map›Paper›PMID 40734538›Full record

ReviewNanomedicine (London, England)2025

Inflammatory microenvironment-responsive MR imaging contrast agents.

Stephen Paige, Jessica Lukac, Ian Stender, Jillian Griffith, Amber L Doiron

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephen PaigeDepartment of Biomedical Engineering, University of Vermont, Burlington, VT, USA.
Jessica LukacDepartment of Biomedical Engineering, University of Vermont, Burlington, VT, USA.
Ian StenderDepartment of Biomedical Engineering, University of Vermont, Burlington, VT, USA.
Jillian GriffithDepartment of Biomedical Engineering, University of Vermont, Burlington, VT, USA.
Amber L DoironDepartment of Biomedical Engineering, University of Vermont, Burlington, VT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a hallmark of numerous acute and chronic diseases, presenting a unique opportunity for molecular imaging. Magnetic resonance imaging, while widely used for its excellent spatial resolution and soft tissue contrast, traditionally lacks the sensitivity and specificity needed to monitor dynamic biochemical processes. To address this gap, a new class of activatable MR imaging contrast agents has emerged - designed to respond selectively to inflammatory triggers such as acidic pH, reactive oxygen species, and proteolytic enzyme activity. This review highlights recent advances in the development of such smart contrast agents, emphasizing their molecular design, activation mechanisms, and preclinical validation. By enabling localized signal enhancement in response to inflammation, these agents offer the potential to improve diagnostic accuracy, stratify disease severity, and monitor therapeutic response with high spatial and temporal resolution. The translation of these agents into clinical practice will depend on continued optimization of stability, safety, and imaging performance across diverse disease models. We performed a literature search using PubMed and Google Scholar for articles published between January 2000 and February 2025 on activatable MR imaging contrast agents, redox-responsive nanoparticles, and imaging of inflammatory processes.

Indexed as

Contrast MediaInflammationMagnetic Resonance ImagingAnimalsHumansNanoparticlesReactive Oxygen SpeciesContrast MediaReactive Oxygen SpeciesActivatable MR contrast agentsenzymesinflammationpHreactive oxygen species

Identifiers

PMID40734538
PMCPMC12330233

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.